1. Home
  2. Stomatitis
  Subject:

Stomatitis   New Search

View on DBpedia    View on Wikipedia
Top related subjects:
 Progression-free survival Enzyme inhibitor Mechanistic target of rapamycin Growth factor Everolimus Estrogen receptor Pharmacokinetics Neutropenia Diarrhea Thrombocytopenia Stomatitis Chemotherapy Multivariate analysis Breast cancer Protein Apoptosis Gene Western blot Messenger RNA Sirolimus Protein kinase B Autophagy Hormone Neu! Blood plasma Bioavailability Biological half-life Pharmacodynamics Anemia Syndrome Fever Constipation
RELATED SUBJECTS:
The publications listed also have these subjects
Progression-free survival  7 times
Enzyme inhibitor  7 times
Mechanistic target of rapamycin  5 times
Growth factor  5 times
Everolimus  5 times
Estrogen receptor  5 times
Pharmacokinetics  4 times
Neutropenia  4 times
Diarrhea  4 times
Thrombocytopenia  3 times
Sunitinib  3 times
Hypertension  3 times
Chemotherapy  3 times
Breast cancer  3 times
Syndrome  2 times
Proteinuria  2 times
Hyperglycemia  2 times
Fluorouracil  2 times
Ferritin  2 times
Creatinine  2 times
Colorectal cancer  2 times
China  2 times
Carcinoma  2 times
Aromatase inhibitor  2 times
Xerostomia  1 time
World Health Organization  1 time
Vitamin B12  1 time
Urinary tract infection  1 time
Tyrosine-kinase inhibitor  1 time
Tuberous sclerosis  1 time
Trastuzumab  1 time
Transcription factor  1 time
Transaminase  1 time
Stomach cancer  1 time
Sorafenib  1 time
Soft-tissue sarcoma  1 time
Sirolimus  1 time
Salivary gland  1 time
Rituximab  1 time
Rhizome  1 time
Randomized controlled trial  1 time
Prime Time Entertainment Network  1 time
Positron  1 time
Pneumonia  1 time
Placebo  1 time
Performance status  1 time
Parotid gland  1 time
Paraneoplastic syndrome  1 time
Pancreatic cancer  1 time
Paclitaxel  1 time
P110α  1 time
Otitis media  1 time
Oral mucosa  1 time
Oncology  1 time
Non-small-cell lung carcinoma  1 time
Nitric oxide  1 time
Neuroendocrine tumor  1 time
Multivariate analysis  1 time
Monoclonal antibody  1 time
Mitogen-activated protein kinase  1 time
Lymphoproliferative disorders  1 time
Lymphoma  1 time
Leukopenia  1 time
Iron-deficiency anemia  1 time
Irinotecan  1 time
International law  1 time
Interleukin-1 family  1 time
Insulin-like growth factor 1 receptor  1 time
Insulin  1 time
Inflammation  1 time
Infection  1 time
IC50  1 time
Hyperphosphatemia  1 time
Histology  1 time
Hematopoietic stem cell transplantation  1 time
Genetic disorder  1 time
Gene  1 time
Gefitinib  1 time
Gastrointestinal tract  1 time
Gastritis  1 time
France  1 time
Folinic acid  1 time
Folic acid  1 time
Fluorescence  1 time
Fibroblast  1 time
Fibrin  1 time
Eastern Cooperative Oncology Group  1 time
Disease  1 time
Determinant  1 time
Dermatitis  1 time
Coeliac disease  1 time
Cmax (pharmacology)  1 time
ClinicalTrials.gov  1 time
Clinical trial  1 time
Cholangiocarcinoma  1 time
CT scan  1 time
CD117  1 time
Blood plasma  1 time
Biopsy  1 time
Biological half-life  1 time
Astrocytoma  1 time
Antibody  1 time
Anemia  1 time
Alkaloid  1 time
Aflibercept  1 time
Adverse drug reaction  1 time
Acne vulgaris  1 time

Publications tagged with this subject: 20

Note: Top 50 publications shown only. Open an item panel to view more info (open all)


1. Value of Soluble Transferrin Receptors and sTfR/log Ferritin in the Diagnosis of Iron Deficiency Accompanied by Acute Infection

2. Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: a practical guide

3. A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma

4. Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea

5. Pazopanib: a Review in Advanced Renal Cell Carcinoma

6. A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer

7. TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies

8. A phase I and pharmacokinetic study of afilbercept with FOLFIRI: comparison of Chinese and Caucasian populations

9. Gefitinib plus Fuzheng Kang’ai Formula (扶正抗癌方) in patients with advanced non-small cell lung cancer with epidermal growth factor receptor mutation: A randomized controlled trial

10. Oral symptoms and salivary findings in oral lichen planus, oral lichenoid lesions and stomatitis

11. A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer

12. Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors

13. Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study

14. Achievement of the longest survival of paraneoplastic pemphigus with bronchiolitis obliterans associated with follicular lymphoma using R-CHOP chemotherapy

15. A prospective observational study on the evaluation of everolimus-related adverse events in metastatic renal cell carcinoma after first-line anti-vascular endothelial growth factor therapy: the AFINITE study in France

16. Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study

17. Identification of anti-inflammatory constituents in Phellodendri Cortex and Coptidis Rhizoma by monitoring the suppression of nitric oxide production

18. Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy

19. Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule

20. Oral Ulcerative Lesions


Questions?

Drop us a message.